GSK’s Emerging Market Sales Solid, Despite China Turbulence
This article was originally published in PharmAsia News
While GSK's overall performance in 2014 may have been lackluster, hit by challenges to its respiratory franchise in the U.S. and flat sales in Europe, emerging markets continued to be an important source of growth. The scandal-hit China business looks set to recover this year after the turbulence of 2014.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.